Back to Search
Start Over
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies
- Source :
- Cancer Letters. 420:242-246
- Publication Year :
- 2018
- Publisher :
- Elsevier BV, 2018.
-
Abstract
- Given the successful identification of epidermal growth factor receptor EGFR T790M, the third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib (OSI, AZD9291), was developed to target EGFR T790M mutation. OSI was approved for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation. However, the disease would progress after the patient received OSI treatment for approximately 10 months. Resistance mechanisms to OSI, such as additional mutation of EGFR and alternative kinase activation, were recently identified, and some novel therapeutic strategies were proposed to overcome OSI resistance. In this review, the resistance mechanisms and therapeutic strategies for OSI-resistant NSCLC were summarized to direct further use of OSI and aid in the development of novel drugs or strategies for OSI-resistant NSCLC.
- Subjects :
- 0301 basic medicine
Cancer Research
Lung Neoplasms
Antineoplastic Agents
Disease
medicine.disease_cause
Piperazines
03 medical and health sciences
0302 clinical medicine
Carcinoma, Non-Small-Cell Lung
Drug Discovery
medicine
Humans
Osimertinib
Epidermal growth factor receptor
Lung cancer
Protein Kinase Inhibitors
Acrylamides
Clinical Trials as Topic
Mutation
Aniline Compounds
biology
Kinase
business.industry
medicine.disease
respiratory tract diseases
Enzyme Activation
ErbB Receptors
030104 developmental biology
Oncology
Drug Resistance, Neoplasm
030220 oncology & carcinogenesis
Cancer research
biology.protein
Non small cell
business
Egfr tyrosine kinase
Subjects
Details
- ISSN :
- 03043835
- Volume :
- 420
- Database :
- OpenAIRE
- Journal :
- Cancer Letters
- Accession number :
- edsair.doi.dedup.....901edfec488dbeb7a87a819fa52e4f79